SAS Output

26-APR-2018 6:10

LEUK ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1312-ALL, CD22+, REL/REF, Inotuzumab+CVP 1 Y 1 CVP + Inotuzumab dose level 1 38 5 0 0 0 0 0 06/13/2014 3 3
        2 CVP + Inotuzumab dose level 2   5 0 0 0 0 0      
        3 CVP + Inotuzumab dose level 3   11 0 0 0 0 0      
        4 CVP + Inotuzumab dose level 4   5 0 0 0 0 0      
        5 CVP + Inotuzumab dose level 5   11 2 0 0 0 0      
        6 CVP + Inotuzumab MTD   1 1 1 1 1 0      
            38 3 1 1 1 0      
 
  S1318-ALL, Age 65+, Ph±, Blinatumomab 1 T 1 Induction: Ph- 44 31 10 0 0 0 0 06/30/2015 154 61
        2 Induction: Ph+/Ph-like   16 0 0 0 0 0      
            47 10 0 0 0 0      
 
    2 Y 3 Post-remission: Ph- 44 20 10 1 0 0 0 06/30/2015    
        4 Post-remission: Ph+/Ph-like   12 8 0 0 0 0      
            32 18 1 0 0 0      
 
    3 Y 5 Maintenance: Ph- 44 14 9 5 1 0 0 06/30/2015    
        6 Maintenance: Ph+/Ph-like   10 8 6 0 0 0      
            24 17 11 1 0 0      
 
  S1612-AML/MDS, Age 60+, Aza/Novel Therapeutics 1 Y 0 FLT3 Testing 1670 17 17 17 17 9 1 02/02/2018   52
            17 17 17 17 9 1      
 
    2 Y 1 Azacitidine 1670 7 7 7 7 4 0 02/02/2018    
        2 Azacitidine + Nivolumab   4 4 4 4 2 0      
        3 Azacitidine + Midostaurin   2 2 2 2 0 0      
            13 13 13 13 6 0      
 
  S0805-Ph+ ALL, Dasatinib/CVAD +/- BMT 1 N 1 Induction/Consolidation 94 97 0 0 0 0 0 08/25/2010 35 14
            97 0 0 0 0 0      
 
    2 Y 2 Vincristine/Pred/Dasatinib   22 0 0 0 0 0 08/25/2010    
            22 0 0 0 0 0      
 
    3 Y 3 Allo stem cell transplant 37 43 0 0 0 0 0 08/25/2010    
            43 0 0 0 0 0      
 
    4 Y 4 Dasatinib   42 0 0 0 0 0 08/25/2010    
            42 0 0 0 0 0      
 
Yes E1910-BCR-ABL-neg, B ALL, Blinatumomab 1 E Total Registrations   80 26 14 6 1 0 06/06/2014 168 86
            80 26 14 6 1 0      
 
  E2906-AML, Age 60+, Clo vs Dauno+Cy 1 E Total Registrations   75 0 0 0 0 0 08/06/2012 150 81
            75 0 0 0 0 0      
 
No E1910-BCR-ABL-neg, B ALL, Blinatumomab 0 E Total Registrations   113 41 20 10 2 0 06/06/2014 168 86
            113 41 20 10 2 0      
 
    2 E Total Registrations   50 15 6 4 1 0 06/06/2014    
            50 15 6 4 1 0      
 
    3 E Total Registrations   41 15 4 3 3 1 06/06/2014    
            41 15 4 3 3 1      
 
    4 E Total Registrations   18 4 3 1 0 0 06/06/2014    
            18 4 3 1 0 0      
 
  E2906-AML, Age 60+, Clo vs Dauno+Cy 0 E Total Registrations   19 0 0 0 0 0 08/06/2012 150 81
            19 0 0 0 0 0      
 
    2 E Total Registrations   21 0 0 0 0 0 08/06/2012    
            21 0 0 0 0 0      
 
    3 E Total Registrations   11 0 0 0 0 0 08/06/2012    
            11 0 0 0 0 0      
 
  NHLBIMDS-LEUK, National MDS Study 1 E Total Registrations   10 7 5 4 1 0 12/22/2016 243 102
            10 7 5 4 1 0